🇺🇸 FDA
Pipeline program

RP-A501

RP-A501-0123

Phase 2 gene_therapy active

Quick answer

RP-A501 for Danon Disease is a Phase 2 program (gene_therapy) at ROCKET PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
ROCKET PHARMACEUTICALS, INC.
Indication
Danon Disease
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials